ClinicalTrials.gg
RecruitingNCT07663864Updated Jun 23, 2026

Luspatercept for CIA in AML

A Phase 1/2 interventional study of Luspatercept Injectable Product in Chemotherapy-inducing Anemia, sponsored by Guangdong Second Provincial General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Guangdong Second Provincial General Hospital · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
248th of 433
40 · median 50
Started
2026
with 55 others
Phase 1/2
66 of 473
39 open now
Primary completion
2026-12
later than 134 of 288 live
Registered
450th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 248th largest by planned enrollment of the 433 interventional ones that give a count, is one of 56 that started in 2026, is one of 66 in phase 1/2, reaches primary completion later than 134 of the 288 other live ones, and was the 450th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

258 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This study aims to explore the feasibility, safety, and preliminary efficacy of rotegcipipone in the treatment of chemotherapy-inducing anemia in AML with a multicenter, prospective, single-arm trial, providing clinical evidence for subsequent clinical development.

Read the detailed description

The application of rotegcipipone in the treatment of chemotherapy-inducing anemia in AML has not yet been systematically studied. Animal studies have shown that rotegcipipone can improve the recovery of anemia after chemotherapy. The bone marrow microenvironment after chemotherapy is often deteriorated due to cytokine storms and hematopoietic stem cell damage, which may further exacerbate erythroid regeneration disorders. Based on rotegcipipone's dual mechanism of improving the hematopoietic microenvironment and promoting erythrocyte maturation, it may overcome the limitations of existing therapies after chemotherapy. Furthermore, its safety profile (primarily grade 1-2 adverse reactions in MDS and β-thalassemia) provides a potential advantage for its application in vulnerable patients after chemotherapy.

03

Conditions studied

  • Chemotherapy-inducing Anemia

Keywords

  • Acute myeloid leukemia
  • Chemotherapy
  • Anemia
  • Luspatercept
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. De novo AML patients;
  2. Age ≥ 18 years and ≤ 60 years;
  3. AML with ELN2022-low risk
  4. Received 1-3 cycles of HDAC consolidation therapy
  5. HGB 60-90 G/L
  6. (ECOG) score ≤ 2 points;
  7. ≥ 3 months;
  8. Signed and able to understand and comply with the procedures required by this protocol.

Exclusion criteria

Exclusion Criteria:

  1. t-AML/sAML
  2. Concurrent myelofibrosis
  3. Patients unresponsive to red blood cell transfusions
  4. Heart function \< grade 2
  5. Renal function: \< 30 ml/min
  6. Liver function: ALTd > 5 times normal, > 3 times normal
  7. Uncontrolled hypertension, defined as recurrent elevations in diastolic blood pressure (DBP) ≥ 100 mmHg despite adequate treatment
  8. History of stroke, deep vein thrombosis (DVT), pulmonary or arterial embolism within 6 months prior to randomization
  9. Uncontrolled systemic fungal, bacterial, or viral infection (defined as persistent infection-related signs/symptoms that do not improve despite appropriate antibiotic, antiviral, and/or other treatments), known (HIV), active virus (HBV) infection, and/or . (HCV) infection
  10. History of severe allergy or allergic reaction to recombinant proteins, or allergy to rotezip or
  11. Pregnant or breastfeeding women
  12. Patients deemed unsuitable for enrollment by the investigators
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Rotesip treatment group

    Patients were screened and enrolled in the treatment group to evaluate the efficacy and safety of rotezipeptide in the treatment of chemotherapy-inducing anemia in AML.

    Drug: Luspatercept Injectable Product

Interventions

  • DrugLuspaterceptStudies of LuspaterceptLuspatercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    First, enrolled patients were randomized to received rotezipeptide with a dosage of 1mg/kg at the day 1 versus day 10 post chemotherapy. Each groups were analyzed to enroll et least 10 patients. Second, after working out which day should be the better one for the treatment of rotezipeptide in phase 1 study, at least 20 patients were enrolled to received rotezipeptide with the same dose at the above day to further work out the efficacy and safety of rotezipeptide in the treatment of CIA in AML.

06

What researchers measure

Primary outcomes

  1. Time of 50% increase in hemoglobin levels from baseline

    The time of hemoglobin levels increasing 50% from baseline

    Time frame: Days 1-28 post chemotherapy

Secondary outcomes

  1. Duration of HGB < 60 G/L during the treatment course (1-28 days)

    The duration of HGB \< 60 G/L during this consolidation treatment course (days 1-28);

    Time frame: Days 1-28 after AML chemistry treatment

  2. Incidence of HGB < 60 G/L during the treatment course (days 1-28)

    The incidence of HGB \< 60 G/L during this consolidation treatment course (days 1-28);

    Time frame: Days 1-28 after chemotherapy

  3. Red blood cell transfusion volume

    Red blood cell transfusion volume during this consolidation treatment course (days 1-28);

    Time frame: Days 1-28 after AML chemistry treamtment

  4. MRD negative rate

    MRD negative rate within 6 months;

    Time frame: 6 months after AML chemistry treamtment

  5. Anemia recurrence rate

    Relapse rate 12 months after chemotherapy;

    Time frame: 12 months after AML chemistry treamtment

Other outcomes

  1. Number of people experiencing treatment-related adverse events

    According to the CTCAE v5.0 assessment, the number of people who experienced treatment-related adverse events included both hematological and non-hematological toxicities.

    Time frame: Days 1-28 after Luspatercept treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

Of 134 non-industry phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 110. This study's planned 6 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2026
First posted
Jun 23, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2027
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07663864
Lead sponsor
Guangdong Second Provincial General Hospital
Collaborators
Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, Guangzhou First People's Hospital, Affiliated Hospital of Guangdong Medical University, Guangzhou 8th People's Hospital
Responsible party
Qing Zhang (Chief Physician, Guangdong Second Provincial General Hospital) — Principal investigator
First posted
Jun 23, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jun 23, 2026

Study contacts

Guopan Yu, PhD
Contact
yugpp@163.com
+8615876559968
Tianmiao Yu, Master
Contact
yutm96@163.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luspatercept

Start the discussion